1. Home
  2. CCIF vs AVTX Comparison

CCIF vs AVTX Comparison

Compare CCIF & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCIF
  • AVTX
  • Stock Information
  • Founded
  • CCIF 2011
  • AVTX 2011
  • Country
  • CCIF United States
  • AVTX United States
  • Employees
  • CCIF N/A
  • AVTX N/A
  • Industry
  • CCIF Finance/Investors Services
  • AVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCIF Finance
  • AVTX Health Care
  • Exchange
  • CCIF Nasdaq
  • AVTX Nasdaq
  • Market Cap
  • CCIF 110.5M
  • AVTX 90.9M
  • IPO Year
  • CCIF N/A
  • AVTX 2015
  • Fundamental
  • Price
  • CCIF $8.01
  • AVTX $9.38
  • Analyst Decision
  • CCIF
  • AVTX Buy
  • Analyst Count
  • CCIF 0
  • AVTX 3
  • Target Price
  • CCIF N/A
  • AVTX $29.50
  • AVG Volume (30 Days)
  • CCIF 76.9K
  • AVTX 90.5K
  • Earning Date
  • CCIF 01-01-0001
  • AVTX 11-07-2024
  • Dividend Yield
  • CCIF 25.90%
  • AVTX N/A
  • EPS Growth
  • CCIF N/A
  • AVTX N/A
  • EPS
  • CCIF N/A
  • AVTX N/A
  • Revenue
  • CCIF N/A
  • AVTX $820,000.00
  • Revenue This Year
  • CCIF N/A
  • AVTX N/A
  • Revenue Next Year
  • CCIF N/A
  • AVTX N/A
  • P/E Ratio
  • CCIF N/A
  • AVTX N/A
  • Revenue Growth
  • CCIF N/A
  • AVTX N/A
  • 52 Week Low
  • CCIF $7.43
  • AVTX $3.95
  • 52 Week High
  • CCIF $10.16
  • AVTX $34.46
  • Technical
  • Relative Strength Index (RSI)
  • CCIF 41.94
  • AVTX 42.72
  • Support Level
  • CCIF $8.12
  • AVTX $9.00
  • Resistance Level
  • CCIF $8.25
  • AVTX $9.82
  • Average True Range (ATR)
  • CCIF 0.07
  • AVTX 0.75
  • MACD
  • CCIF 0.00
  • AVTX 0.01
  • Stochastic Oscillator
  • CCIF 32.00
  • AVTX 27.86

About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest

Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing primarily in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting primarily of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Share on Social Networks: